GoldenGolden
Advanced Search
Kymera Therapeutics

Kymera Therapeutics

Kymera Therapeutics is a Cambridge, Massachusetts-based biotechnology company specialized in the field of targeted protein degradation.

Kymera Therapeutics is a clinical stage biopharmaceutical company that is developing novel protein degrader therapeutics for treating disease in effective new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of removing them from the body. Kymera Therapeutics is driven to invent transformative medicines for a broad variety of diseases where traditional drug modalities have failed to adequately unlock the appropriate biological solution.

The company is pioneering a transformative new modality, “targeted protein degradation” (TPD), with the capability to pursue targets long considered undruggable and to treat disease in new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to better the lives of patients with serious diseases.

Its team has developed a proprietary drug discovery engine, Pegasus, to allow the design of highly selective, small molecule protein degraders with potent activity against a wide range of disease indications. The company is committed to selecting targets with the widest possible impact across multiple disease indications with unmet medical need to realize the full potential of TPD.

Timeline

March 12, 2020
Kymera Therapeutics raises a $102,000,000 series C round from Biotechnology Value Fund.
November 13, 2018
Kymera Therapeutics raises a $65,000,000 series B round from 6 Dimensions Capital.
October 30, 2017
Kymera Therapeutics raises a $30,000,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 21, 2021
BioSpace
Data presented at the 16th ICML Meeting demonstrate KT-413's potent antitumor activity as a monotherapy compared to a clinically active IRAK4 kinase inhibitor or a latest generation IMiD in MYD88-mutant mouse xenograft model.
BioSpace
June 9, 2021
BioSpace
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that an abstract featuring new preclinical data for its IRAKIMiD degrader KT-413 has been selected for oral presentation at the 16th Annual International Conference.
BioSpace
May 10, 2021
BioSpace
New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory models KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK4 degrader for the treatment of immune-inflammatory diseases, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and potentially others
BioSpace
May 5, 2021
BioSpace
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology.
BioSpace
April 19, 2021
BioSpace
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ) has named Kymera Therapeutics to its 2021 Best Places to Work, an exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.
Alex Keown
April 12, 2021
BioSpace
In a flurry of weekend activity, oncology companies showcased the latest clinical and preclinical data for cancer therapies during the virtual American Association for Cancer Research meeting.
BioSpace
April 10, 2021
BioSpace
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models compared to IMiDs or selective IRAK4 targeting alone
Ben Adams
July 9, 2020
FierceBiotech
While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it's penned a big one with Fierce 15 winner Kymera Therapeutics.
BioSpace
June 11, 2020
BioSpace
Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced that it will present preclinical data on its potent and highly selective STAT3 degraders as well as the first data from its novel IRAKIMiD degraders combining IRAK4 and IMiD substrate degradation.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.